It has been reported to decrease fibrosis and glomerulosclerosis in diabetic nephropathy by inhibiting the PPARy/TGF-β pathway and reversing expression of Bmp6 and Mmp1357. This evidence concerns the gene TGFB1 and diabetic kidney disease.